Skip to main content
. Author manuscript; available in PMC: 2015 Nov 9.
Published in final edited form as: Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):56–66. doi: 10.2174/18722083113079990008

Table 2.

The changes in lipid parameters.

Group Duration of the study, months
0 3 6 9 12 18 24
Total cholesterol, mMol/L
Allicor 6.14±0.12 6.01±0.13 6.01±0.13 6.09±0.13 6.05±0.13 6.03±0.12 6.01±0.14
Placebo 6.02±0.10 6.20±0.11* 6.20±0.12* 6.35±0.12* 6.34±0.13* 6.32±0.12* 6.29±0.13*
HDL cholesterol, mMol/L
Allicor 1.07±0.03 1.15±0.04* 1.15±0.03* 1.24±0.04* 1.29±0.04* 1.32±0.03* 1.34±0.04*
Placebo 1.10±0.03 1.18±0.03* 1.24±0.04* 1.25±0.03* 1.34±0.04* 1.29±0.04* 1.23±0.04*
LDL cholesterol, mMol/L
Allicor 4.06±0.10 3.85±0.11*# 3.94±0.11 3.96±0.11 3.87±0.11* 3.89±0.11*# 3.85±0.12*#
Placebo 3.88±0.09 4.16±0.10* 4.09±0.11* 4.23±0.11* 4.11±0.11* 4.19±0.10* 4.24±0.12*
Triglycerides, mMol/L
Allicor 2.17±0.14 2.18±0.13# 1.99±0.12 1.91±0.11* 1.91±0.12* 1.87±0.13* 1.88±0.12*
Placebo 2.23±0.12 1.86±0.08* 1.87±0.10* 1.87±0.09* 1.95±0.12* 1.92±0.12* 1.89±0.10*
*

, significant difference from the baseline, paired test, P<0.05

#

, significant difference from placebo, independent samples test, P<0.05